Hot Pursuit     30-May-24
Marksans Pharma declines after Q4 PAT slides 6% YoY to Rs 78 cr
Marksans Pharma tumbled 10.30% to Rs 151.90 after the company reported 6.12% decline in consolidated net profit to Rs 77.64 crore in Q4 FY24 from Rs 82.71 crore in Q4 FY23.
Revenue from operations jumped 15.23% YOY to Rs 560.01 crore in Q4 FY24, driven by volume gains, new launches, addition of new customers, and increase in our share with existing customers.

Profit before tax fell 3.74% to Rs 100.27 crore in Q4 FY24 as compared to Rs 104.17 crore in Q4 FY23.

EBITDA rose marginally to Rs 109.6 crore in Q4 FY24 as compared to Rs 109.5 crore in Q4 FY23. EBITDA margin reduced to 19.6% in the fourth quarter as compared to 22.5% in the corresponding period last year, surge in freight cost, transit time due to red sea crisis, increase in expenses related to Teva acquisition and increased hiring in the new plant in Q4FY24 led to impact on EBITDA.

During the quarter, revenue from US & North America stood at Rs 245 crore (up 26.5% YoY) while UK and Europe stood at Rs 232.8 crore (up 12.9% YoY).

Revenue from Australia and New Zealand business stood at Rs 63.3 crore (down 0.1% YoY) in Q4 FY24.

Rest of World (ROW) business de-grew by 17.1% YoY to Rs 18.9 crore during the period under review.

On a full year basis, the company reported a consolidated profit climbed 18.68% to Rs 314.89 crore on 17.56% increase in revenue from operations 2,177.40 crore in FY24 over FY23.

Meanwhile, the board has declared a dividend of Rs 0.60 per share for the financial year ended 2024, The dividend will be paid within 30 days from the date of the AGM.

Mark Saldanha, managing director, Marksans Pharma, said, “We are delighted to report a strong performance in FY24 in terms of both revenue and profitability. Our operating revenue for the year grew year-on-year by 18% and EBITDA increased by 35%, supported by new product launches, increase in market share, reduction in raw material prices and operating leverage. This year we have not only met but exceeded our revenue target of Rs 2,000 crore.

We remain confident on delivering sustained long-term value for our shareholders, as we position ourselves strongly in terms of infrastructure, product mix and long-term customer relationships.”

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulations.

Previous News
  Marksans Pharma consolidated net profit rises 14.97% in the June 2023 quarter
 ( Results - Announcements 12-Aug-23   07:46 )
  Marksans Pharma schedules board meeting
 ( Corporate News - 28-Oct-23   17:27 )
  Marksans Pharma jumps after Q3 PAT climbs 34% YoY to Rs 83 cr
 ( Hot Pursuit - 13-Feb-24   15:41 )
  Marksans Pharma to conduct board meeting
 ( Corporate News - 02-Feb-22   10:54 )
  Marksans Pharma consolidated net profit rises 95.34% in the September 2020 quarter
 ( Results - Announcements 06-Nov-20   15:36 )
  Marksans Pharma to hold board meeting
 ( Corporate News - 11-Jun-21   12:27 )
  Marksans Pharma reports standalone net profit of Rs 4.33 crore in the March 2018 quarter
 ( Results - Announcements 01-Jun-18   16:32 )
  Marksans Pharma to convene board meeting
 ( Corporate News - 02-Aug-22   10:50 )
  Marksans Pharma receives UK MHRA approval for Bells Healthcare All in One Oral Solution
 ( Corporate News - 22-Feb-22   14:05 )
  Marksans Pharma consolidated net profit declines 9.65% in the June 2019 quarter
 ( Results - Announcements 10-Aug-19   11:37 )
  Marksans Pharma consolidated net profit rises 333.91% in the March 2020 quarter
 ( Results - Announcements 02-Jun-20   12:02 )
Other Stories
  Inox Green Energy board OKs fund raising proposal
  22-Jun-24   17:00
  Cipla Goa facility gets 6 USFDA observations
  22-Jun-24   16:22
  EIH CFO Kallol Kundu resigns
  22-Jun-24   14:20
  Sky Gold acquires entire stake in Starmangalsutra & Sparkling Chains
  22-Jun-24   13:31
  TVS Motor inks pact with CSC Grameen eStores for its CV range
  22-Jun-24   12:27
  Prestige Estates to raise Rs 5000 crore via QIP
  22-Jun-24   11:59
  JSW Energy arm bags LoA from SECI
  22-Jun-24   10:56
  RVNL emerges as L-1 bidder for Rs 191-cr railway project
  22-Jun-24   09:54
  Bajaj Consumer hits 52-week high as board OKs Rs 166-cr share buyback
  21-Jun-24   15:28
  GRM Overseas rallies as board OKs Rs 136-cr preferential issue
  21-Jun-24   15:19
Back Top